风湿性关节炎的医疗治疗取得了进展
Stephanie Tancer1, Beth I Wallace2
1Cleveland Clinic Orthopedic and Rheumatologic Institute, 1730 West 25th Street, Cleveland, OH 44113, USA.
Hand clinics
|November 9, 2024
概括
类风湿性关节炎 (RA) 是一种具有关节和全身症状的自身免疫性疾病. 了解RA病原学的进步导致了新的向治疗方法,以及对疫苗接种和生殖健康的考虑.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 自免疫性疾病 自免疫性疾病
背景情况:
- 类风湿性关节炎 (RA) 是一种普遍存在的慢性自身免疫性疾病.
- RA 影响关节,并可能导致关节外的表现.
- 在了解RA病原发生方面取得了重大进展.
研究的目的:
- 审查RA的临床表现.
- 讨论RA的发病过程.
- 概述RA的当前和新型治疗策略,包括特殊考虑.
主要方法:
- 关于类风湿性关节炎的文献综述.
- 综合有关临床表现,病原和治疗的信息.
- 包括生殖健康,疫苗接种和术后管理方面的具体考虑.
主要成果:
- 关节炎呈现出各种各样的关节和关节外症状.
- 新型向疗法已经出现,这是由于对RA病变的理解有所改善.
- 管理策略包括标准护理和特定患者群体需求.
结论:
- 风险管理需要全面的管理,应对其多方面的性质.
- 治疗的进步为类风湿性关节炎患者提供了更好的结果.
- 专业考虑对于在特定情况下优化RA护理至关重要.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120
Autoimmune Disorders
398
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
398
Inflammatory Bowel Disease IV: Pharmacological Management
122
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
122
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
98
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
98
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
404
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404


